Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (261-270 of 350) with videos related to

Pageof 35
Sort By:
Journal of Biological Response Modifiers|June 1, 1986
Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexonY Z Patt, G M Mavligit, J Reuben, et al.
Leukemia|June 1, 1989
Myeloproliferative disorders: usefulness of X-linked probes in diagnosisK M Taylor, M Shetta, M Talpaz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 5, 2002
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantationA Shimoni, J A Gajewski, M Donato, et al.
Bone Marrow Transplantation|July 1, 1994
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemiaH M Kantarjian, M Talpaz, B Andersson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemiaS Sacchi, H M Kantarjian, T L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabineH M Kantarjian, M J Keating, E H Estey, et al.
Experimental Hematology|August 1, 1992
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitorsZ Estrov, C H Park, C L Reading, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapyM Shtalrid, M Talpaz, M Blick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I studyK H Lee, M Talpaz, J M Rothberg, et al.
The Journal of Experimental Medicine|March 1, 1993
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell linesZ Estrov, R Kurzrock, E Pocsik, et al.
Pageof 35

Showing results (261-270 of 350) with videos related to

Sort By:
Pageof 35
Journal of Biological Response Modifiers|June 1, 1986
Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexonY Z Patt, G M Mavligit, J Reuben, et al.
Leukemia|June 1, 1989
Myeloproliferative disorders: usefulness of X-linked probes in diagnosisK M Taylor, M Shetta, M Talpaz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 5, 2002
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantationA Shimoni, J A Gajewski, M Donato, et al.
Bone Marrow Transplantation|July 1, 1994
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemiaH M Kantarjian, M Talpaz, B Andersson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemiaS Sacchi, H M Kantarjian, T L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabineH M Kantarjian, M J Keating, E H Estey, et al.
Experimental Hematology|August 1, 1992
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitorsZ Estrov, C H Park, C L Reading, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapyM Shtalrid, M Talpaz, M Blick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I studyK H Lee, M Talpaz, J M Rothberg, et al.
The Journal of Experimental Medicine|March 1, 1993
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell linesZ Estrov, R Kurzrock, E Pocsik, et al.
Pageof 35